Catheter lock solution
Catheter lock solution of which one type is sold under the brand name Neutrolin are a number of solutions put into catheters. Neutrolin is an anti-microbial catheter lock solution developed by Cormedix/Cormedix GmbH. A catheter lock solution is used to fill the catheter when not in use, primarily to prevent clotting. Neutrolin contains heparin and citrate (1000 U/mL and 3.5% respectively), two compounds commonly used to prevent thrombosis and maintain catheter potency.
Neutrolin also contains taurolidine, an anti-microbial agent that has been shown to be safe and effective in preventing bacterial colonization of catheters  No resistance to taurolidine has been observed to date.
- Neutrolin Product Brochure.
- Solomon, L.R.; et al. (June 2010). "A Randomized Double-Blind Controlled Trial of Taurolidine-Citrate Catheter Locks for the Prevention of Bacteremia in Patients Treated with Hemodialysis". American Journal of Kidney Diseases. 55 (6): 1060–1068. doi:10.1053/j.ajkd.2009.11.025. PMID 20207458.
- Koldehoff M.; Zakrzewski J.L. (June 2004). "Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients". International Journal of Antimicrobial Agents. 24 (5): 491–495. doi:10.1016/j.ijantimicag.2004.06.006. PMID 15519483.
- Simon A.; Ammann R.A.; Wiszniewsky G.; Bode U.; Fleischhack G. & Besuden M.M. (June 2008). "Taurolidine-citrate lock solution significantly reduces CVAD-associated grampositive infections in pediatric cancer patients". BMC Infectious Diseases. 8: 102. doi:10.1186/1471-2334-8-102. PMC . PMID 18664278.
- Betjes M.G.H. & van Agteren M. (February 2004). "Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution". Nephrol Dial Transplant. 19 (6): 1546–1551. doi:10.1093/ndt/gfh014. PMID 14993498.
- Handrup M.M., Moller, J.K., and Schroder, H. (February 2013). "Central Venous Catheters and Catheter Locks in Children With Cancer: A Prospective Randomized Trial of Taurolidine Versus Heparin". Pediatr Blood Cancer. 60 (8): 1292–1298. doi:10.1002/pbc.24482. PMID 23417891.